5-甲基-1,3-二氢苯并咪唑-2-酮 | 5400-75-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-甲基-1,3-二氢苯并咪唑-2-酮
• 中文别名: 5-甲基苯并咪唑酮；5-甲基-2(3H)-苯并咪唑酮；1H-苯并咪唑-2-醇,5-甲基-；2H-苯并咪唑-2-酮,1,3-二氢-5-甲基-；5-甲基-1,3-二氢-2H-苯并咪唑-2-酮
• 英文名称: 5-methyl-1,3-dihydro-2H-benzimidazol-2-one
• 英文别名: 5-methyl-1,3-dihydrobenzimidazol-2-one；5-methyl-1H-benzo[d]imidazol-2(3H)-one；1,3-dihydro-5-methyl-2H-benzimidazol-2-one；5-methylbenzimidazol-2-one；5-methylbenzimidazolone；5-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one；5-methyl-1,3-dihydrobenzoimidazol-2-one；5-Methyl-benzimidazolin-2-on；5-Methyl-2-benzimidazolinon；5-Methyl-benzimidazolon；NSC 10384
• CAS: 5400-75-9
• 化学式: C₈H₈N₂O
• mdl: MFCD00754728
• 分子量: 148.164
• InChiKey: CTCHXZUMFHNSHM-UHFFFAOYSA-N

物化性质

• 熔点：
  292 °C(Solv: ethanol (64-17-5))
• 沸点：
  147.7±10.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Methylbenzoimidazol-2(3H)-one
Synonyms: 5-Methyl-1H-benzo[d]imidazol-2(3H)-one

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Methylbenzoimidazol-2(3H)-one
CAS number: 5400-75-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8N2O
Molecular weight: 148.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-1,3-二氢苯并咪唑-2-酮 在 一水合肼 、 三氯氧磷 作用下， 反应 9.0h， 生成 2-肼基-5-甲基-1H-苯并咪唑
  参考文献：
  名称：

  NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF

  摘要：

  本发明旨在提供一种能够抑制PCA-1的化合物，该化合物可作为各种疾病的新型治疗方法的靶点，并且可用于制药的该化合物。一种由以下化学式（I）表示的化合物：其中每个符号如描述中定义的，或其药用盐。

  公开号：

  US20150011600A1
• 作为产物：
  描述：

  N-氰基甲基-4-甲基-2-硝基苯胺 在 硫酸 作用下， 以 溶剂黄146 为溶剂， 100.0~750.0 ℃ 、9.33 Pa 条件下， 反应 2.5h， 生成 5-甲基-1,3-二氢苯并咪唑-2-酮
  参考文献：
  名称：

  Harvey, Ian W.; McFarlane, Michael D.; Moody, David J., Journal of the Chemical Society. Perkin transactions I, 1988, p. 681 - 690

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2010137738A1

  公开（公告）日：2010-12-02

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新颖的杂环化合物。一种由通式（1）表示的杂环化合物，其中，R1和R2分别独立表示氢；苯基较低烷基基团，可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基；或环C3-C8烷基较低烷基基团；或类似物；R3表示较低炔基基团或类似物；R4表示可能具有从1,3,4-噁二唑基团（例如，卤素）或从吡啶基团等组成的取代基的苯基团；所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Scope of chemical fixation of carbon dioxide catalyzed by a bifunctional monomeric tungstate
  作者：Keigo Kamata、Toshihiro Kimura、Hanako Sunaba、Noritaka Mizuno

  DOI：10.1016/j.cattod.2013.09.054

  日期：2014.5

  corresponding carbamic acid intermediates. The present bifunctionality could be applied to chemical fixation of CO2 even at atmospheric pressure with various kinds of structurally diverse aryl diamines, primary monoamines, propargylic alcohols, and propargylic amines into cyclic urea derivatives, 1,3-disubstituted urea derivatives, cyclic carbonates, and cyclic carbamates, respectively.

  简单的单体钨酸盐TBA 2 [WO 4 ]（I，TBA =四正丁基铵）中的钨-氧羰基部分同时显示出CO 2和1,2-苯二胺（1a）的双功能活化。通过1 H，13 C和183 W NMR光谱证实，加合物I-1a和I-（CO 2）n（n  = 1和2）是由I与1a和CO 2的反应形成的。， 分别。这些加合物在形成相应的氨基甲酸中间体中起重要作用。本双功能可应用于CO的化学固定2即使在与各种结构不同的芳基二胺，伯单胺，炔丙醇，炔丙基和胺成环状脲衍生物，1,3-二取代的脲衍生物，环状碳酸酯大气压，和环状氨基甲酸酯。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DERIVES DE BENZIMIDAZOLES ET UTILISATION DE CEUX-CI EN TANT QUE LIGANDS DU RECEPTEUR VANILLOIDE
  申请人：AMGEN INC

  公开号：WO2004035549A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

  式（I）的化合物在治疗辣椒素受体介导的疾病方面很有用，如炎症性或神经病痛以及涉及感觉神经功能的疾病，如哮喘、类风湿性关节炎、骨关节炎、炎症性肠道疾病、尿失禁、偏头痛和牛皮癣。